Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 2/20 | 0.50 |
| ▸ | MCHR1 | Q99705 | 5/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.47 |
| ▸ | DRD4 | P21917 | 1/20 | 0.47 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | NAMPT | P43490 | 1/20 | 0.45 |
| ▸ | SSTR1 | P30872 | 1/20 | 0.45 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1908695 | 0.88 | DRD4 (0.52) | SMN1; SMN2RAB9ANPC1MCHR1HRH3 | |
| SCHEMBL1908665 | 0.85 | F2 (0.49) | SMN1; SMN2RAB9ADRD4EPHX1HPGD | |
| SCHEMBL13242298 | 0.84 | DRD4 (0.66) | SMN1; SMN2RAB9AMCHR1EPHX2DRD4 | |
| SCHEMBL4012079 | 0.83 | EPHX2 (0.56) | SMN1; SMN2RAB9ANPC1MCHR1HRH3 | |
| SCHEMBL358475 | 0.81 | NAMPT (0.64) | SMN1; SMN2RAB9ADRD4EPHX1HPGD | |
| SCHEMBL4214296 | 0.80 | CHKA (0.50) | SMN1; SMN2EPHX2DRD4HPGDALDH1A1 | |
| SCHEMBL1912275 | 0.80 | EPHX2 (0.56) | SMN1; SMN2NPC1EPHX2EPHX1HPGD | |
| SCHEMBL13700889 | 0.80 | EPHX2 (0.56) | SMN1; SMN2NPC1EPHX2EPHX1HPGD | |
| SCHEMBL14026514 | 0.80 | EPHX2 (0.56) | SMN1; SMN2NPC1EPHX2EPHX1HPGD | |
| SCHEMBL12084206 | 0.80 | EPHX2 (0.56) | SMN1; SMN2NPC1EPHX2EPHX1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-8114877-B2 | Antiinflammatory agnets; chronic obstructive pulmonary diseases | NOVARTIS AG (CH) | 2012-02-14 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20090093633-A1 | Organic Compounds | NOVARTIS AG | 2009-04-09 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
| US-20080207648-A1 | Organic Compounds | NOVARTIS AG (CH) | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093633-A1 | Organic Compounds | ADORA2A, ADORA3, ADORA1 | SMN1; SMN2 3129/4885RAB9A 2373/4885NPC1 762/4885 |
| US-20080207648-A1 | Organic Compounds | ADORA2A, ADORA1, ADORA3 | SMN1; SMN2 3845/4885RAB9A 2513/4885NPC1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.